News About SaNOtize Nasal Spray (Enovid)

"The Power of NO: How a Tiny Natural Molecule Can Help Shift How We Treat Covid-19 and Other Infections While more work needs to be done, the current research into new delivery platforms for nitric oxide is extremely promising. We hope to see the molecule play an increasingly prominent role in treatment and prevention strategies for common infections – and in so doing help...

"Enovid, an innovative anti-viral spray developed in Canada by an Israeli researcher and manufactured in Israel, has been proven effective in preventing viruses – including COVID-19 – from entering the body through the nasal cavity."   Published: JANUARY 3, 2023 12:13 on the Jerusalem post, click to READ MORE

There are currently zero authorized or approved preventative COVID therapies in the U.S. but Canadian biotech SaNOtize wants to change that, charting plans to move a nasal spray into a phase 3 study as soon as October.  It’s a deviation for the company that until now has been developing the nitric oxide nasal spray (NONS) as an early antiviral treatment, primarily assessing a reduction...

SaNOtize has raised a $24 million series B round, giving it the cash to fund its ongoing phase 3 COVID-19 prevention trial and other research into its nitric oxide nasal spray (NONS).   The Vancouver-based company set up shop in 2017 to unlock the antimicrobial properties of nitric oxide. Using its nitric oxide releasing solution platform, SaNOtize sought to enable the use of the molecule in...

Published on May 11, 2022 on Businesswire.com. After confirmed exposure to COVID-19, infection rate in participants (n=625) who took NONS™ was 6.4% versus 25.6% in the control group (P<0.0001). The new data build upon previously reported Phase III trial results demonstrating that a rapid reduction of viral load prevents progression to infection after COVID-19 exposure. The new study, conducted at Srinakharinwirot University in Bangkok,...